NRL-1049

NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice .


Cat. No.: EX-A15104	Purity: >98%

	Chemical structure of NRL-1049

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
1g	2386	Inquire
5g	get quote	Inquire
10g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	BA-1049
CAS No.	1973494-16-4
Purity	>98%
Formula	C16H21N3O2S
Mol Weight	319.422
Color	White to off-white
State	Solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; 4℃, 2 years; In solvent -20℃, 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Mulder IA, et al. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury. J Cereb Blood Flow Metab. 2024;44(11):1238-1252. [2]. Madden S, et al. Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial. CNS Drugs. 2025;39(9):865-877.
CoA	CoA of NRL-1049

Smiles:	C[C@H](C1CCN(CC1)S(=O)(C2=C3C=CN=CC3=CC=C2)=O)N


		Search